This clinical trial is positioned to evaluate the efficacy and safety of Venetoclax in combination with a 3-day Decitabine regimen compared to the established Venetoclax and Azacitidine regimen in elderly or unfit patients with newly diagnosed Acute Myeloid Leukemia (AML). The target population is significant, as elderly patients represent a substantial segment of the AML market, often facing limited treatment options due to comorbidities. If successful, this trial could provide a competitive edge for Venetoclax in the AML treatment landscape, potentially expanding its market share against existing therapies. The trial's outcomes may influence treatment guidelines and reimbursement policies, thus impacting commercial strategies for stakeholders involved in AML therapeutics.